These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25156796)

  • 1. Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis.
    Zhang XQ; Even-Or O; Xu X; van Rosmalen M; Lim L; Gadde S; Farokhzad OC; Fisher EA
    Adv Healthc Mater; 2015 Jan; 4(2):228-36. PubMed ID: 25156796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr
    Yu M; Amengual J; Menon A; Kamaly N; Zhou F; Xu X; Saw PE; Lee SJ; Si K; Ortega CA; Choi WI; Lee IH; Bdour Y; Shi J; Mahmoudi M; Jon S; Fisher EA; Farokhzad OC
    Adv Healthc Mater; 2017 Oct; 6(20):. PubMed ID: 28730752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of therapeutic polymeric nanoparticles for the resolution of inflammation.
    Gadde S; Even-Or O; Kamaly N; Hasija A; Gagnon PG; Adusumilli KH; Erakovic A; Pal AK; Zhang XQ; Kolishetti N; Shi J; Fisher EA; Farokhzad OC
    Adv Healthc Mater; 2014 Sep; 3(9):1448-1456. PubMed ID: 24659608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.
    van der Hoorn J; Lindén D; Lindahl U; Bekkers M; Voskuilen M; Nilsson R; Oscarsson J; Lindstedt E; Princen H
    Br J Pharmacol; 2011 Apr; 162(7):1553-63. PubMed ID: 21175581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression.
    Guo Y; Yuan W; Yu B; Kuai R; Hu W; Morin EE; Garcia-Barrio MT; Zhang J; Moon JJ; Schwendeman A; Eugene Chen Y
    EBioMedicine; 2018 Feb; 28():225-233. PubMed ID: 29361501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo.
    Yasuda T; Grillot D; Billheimer JT; Briand F; Delerive P; Huet S; Rader DJ
    Arterioscler Thromb Vasc Biol; 2010 Apr; 30(4):781-6. PubMed ID: 20110577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model.
    Briand F; Tréguier M; André A; Grillot D; Issandou M; Ouguerram K; Sulpice T
    J Lipid Res; 2010 Apr; 51(4):763-70. PubMed ID: 19965597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease.
    Fessler MB
    Pharmacol Ther; 2018 Jan; 181():1-12. PubMed ID: 28720427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo.
    Naik SU; Wang X; Da Silva JS; Jaye M; Macphee CH; Reilly MP; Billheimer JT; Rothblat GH; Rader DJ
    Circulation; 2006 Jan; 113(1):90-7. PubMed ID: 16365197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement Receptor Targeted Liposomes Encapsulating the Liver X Receptor Agonist GW3965 Accumulate in and Stabilize Atherosclerotic Plaques.
    Benne N; Martins Cardoso R; Boyle AL; Kros A; Jiskoot W; Kuiper J; Bouwstra J; Van Eck M; Slütter B
    Adv Healthc Mater; 2020 May; 9(10):e2000043. PubMed ID: 32329226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of mannose functionalized dendrimeric nanoparticles for targeted delivery to macrophages: use of this platform to modulate atherosclerosis.
    He H; Yuan Q; Bie J; Wallace RL; Yannie PJ; Wang J; Lancina MG; Zolotarskaya OY; Korzun W; Yang H; Ghosh S
    Transl Res; 2018 Mar; 193():13-30. PubMed ID: 29172034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of chronic damage in renal allografts by Liver X receptor (LXR) activation relevant contribution of macrophage LXRα.
    Kiss E; Popovic Z; Bedke J; Wang S; Bonrouhi M; Gretz N; Stettner P; Teupser D; Thiery J; Porubsky S; Adams J; Gröne HJ
    Am J Pathol; 2011 Jul; 179(1):92-103. PubMed ID: 21703396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LXR driven induction of HDL-cholesterol is independent of intestinal cholesterol absorption and ABCA1 protein expression.
    Kannisto K; Gåfvels M; Jiang ZY; Slätis K; Hu X; Jorns C; Steffensen KR; Eggertsen G
    Lipids; 2014 Jan; 49(1):71-83. PubMed ID: 24163219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice.
    Skerrett R; Pellegrino MP; Casali BT; Taraboanta L; Landreth GE
    J Biol Chem; 2015 Aug; 290(35):21591-602. PubMed ID: 26163517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR(-/-) mice.
    Peng D; Hiipakka RA; Xie JT; Dai Q; Kokontis JM; Reardon CA; Getz GS; Liao S
    Br J Pharmacol; 2011 Apr; 162(8):1792-804. PubMed ID: 21232031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke.
    Morales JR; Ballesteros I; Deniz JM; Hurtado O; Vivancos J; Nombela F; Lizasoain I; Castrillo A; Moro MA
    Circulation; 2008 Sep; 118(14):1450-9. PubMed ID: 18794391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal muscle as a target of LXR agonist after long-term treatment: focus on lipid homeostasis.
    Archer A; Laurencikiene J; Ahmed O; Steffensen KR; Parini P; Gustafsson JÅ; Korach-André M
    Am J Physiol Endocrinol Metab; 2014 Mar; 306(5):E494-502. PubMed ID: 24368671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LXR as a novel antithrombotic target.
    Spyridon M; Moraes LA; Jones CI; Sage T; Sasikumar P; Bucci G; Gibbins JM
    Blood; 2011 May; 117(21):5751-61. PubMed ID: 21411760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver X receptor: a potential target in the treatment of atherosclerosis.
    Savla SR; Prabhavalkar KS; Bhatt LK
    Expert Opin Ther Targets; 2022 Jul; 26(7):645-658. PubMed ID: 36003057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator.
    Miao B; Zondlo S; Gibbs S; Cromley D; Hosagrahara VP; Kirchgessner TG; Billheimer J; Mukherjee R
    J Lipid Res; 2004 Aug; 45(8):1410-7. PubMed ID: 15145986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.